AzTrials
AzTrials

Diabetes Mellitus, Type 2NCT04712916

Pharmacist-led Intervention in Treatment Non-adherence in Southwestern Nigeria

A study testing Health education in people with Diabetes Mellitus, Type 2, run by University of Ibadan at 1 site in Nigeria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Summary of the Research Medication non-adherence has a huge economic impact on the patient and the society at large. World Health Organization (WHO) has suggested that noncompliance with medication is a common problem which often leads to compromised health benefits and serious economic consequences in terms of wasted… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Diabetes Mellitus, Type 2
What is being tested?
Health education
Could I receive a placebo?
No, everyone receives an active treatment
How many people
401 participants
Where
1 siteNigeria
Study dates
10 Jun 2017to 20 Sep 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adult out-patients diagnosed and being managed for T2D or hypertension or the co-morbid diseases.
  • Participants must have been on antidiabetes/or antihypertensive medication(s) for at least six-months prior to their recruitment to the study.

Who cannot join

  • Newly diagnosed T2D and hypertensive patients
  • Pregnant women with diabetes or hypertension.
  • Unconscious patients and those booked for admission.
  • Patients less than 18 years of age.

Trial locations and contacts

1 site in 1 country.

Nigeria1 site
  • University College Hospital

    Ibadan, Oyo State, 234

Other trials in Nigeria

About this study

Official title: Pharmacist-led Intervention in Treatment Non-adherence and Costs of Management Among Ambulatory Type 2 Diabetes and Hypertensive Patients in Southwestern Nigeria

Summary of the Research Medication non-adherence has a huge economic impact on the patient and the society at large. World Health Organization (WHO) has suggested that noncompliance with medication is a common problem which often leads to compromised health benefits and serious economic consequences in terms of wasted time, money and increased morbidity. Other consequences are waste of medication, disease progression, reduced functional abilities, lower quality of life, and increased use of medical resources such as nursing homes, hospital visits and hospital admissions. Non-adherence is common to patients with chronic diseases, such as hypertension and diabetes, compared to patients with acute conditions. The annual cost of medication non-adherence, which includes hospital and nursing home admissions, increased ambulatory costs, lost productivity and premature deaths, has been estimated to be more than $100 billion per year in the United States. In Canada, hospital expenditures caused by non-adherence was estimated to be more than US$1.6 billion. The potential burden of medication non-adherence outcomes on health care delivery makes it an important public health concern.

Many studies have addressed non-adherence to medication in developed countries. Past studies on non-adherence in Nigeria have identified different rates of non-adherence to medications for disease states such as diabetes mellitus and hypertension. Literature is scanty on studies on cost of non-adherence in Nigeria. This study will be focus on cost implications of non-adherence to treatment among patients of selected disease states (hypertension and type 2 diabetes mellitus).

Read more

Research design The study was a quasi-experimental study among T2D patients that were recruited from the two hospitals using questionnaire-guided semi-structured interview. At the baseline, participants with HbA1c ≥7% were classified as uncontrolled/intervention group, while those with HbA1c <7% were considered as control group. Similarly, participants with blood pressure <140/90mmHg were classified as control/adherent while those with blood pressure ≥140/900mmHg were uncontrolled/intervention group.

Methodology A quasi-experimental study among 201-patients with T2D using semi-structured interview. Baseline questionnaire comprised modified 4-items Medication Adherence Questions (MAQ), Perceived Dietary Adherence Questionnaire (PDAQ) and International Physical Activity Questionnaire, to assess participants' adherence to medications, diet and physical activity, respectively. Patients were assigned into control (HbA1c<7%, n=95) and intervention (HbA1c≥7%, n=106) groups. Post-baseline, participants were follow-up for 6-months with educational intervention provided to clarify and resolve identified discrepancies among the intervention group only, while the control group continued to receive the usual care. Costs of management including transportation fare, consultation fee, medications and laboratory investigations were estimated for 6-months pre-baseline and 6-months post-baseline for both groups. Data were summarized using descriptive statistics, while Chi-square, McNemar and paired t-test were used for categorical and continuous variables at p<0.05.

Principal exposure: Glycated haemoglobin HbA1c, was measured for Type 2 DM participants and blood pressure was taken for hypertensive participants Outcome variable: Effect of pharmacist-led intervention on therapy non-adherence, reasons for non-adherence and costs of management.

Read the detailed description

The study involved adult T2D, hypertensive and those with the two diseases attending the cardiology and endocrinology out-patient clinics of the two tertiary hospitals [University College Hospital (UCH), Ibadan and Federal Medica Centre (FMC), Abeokuta, Nigeria].

Sample size determination

For the prospective phase, an average of 25 patients regularly attend the weekly medical out-patient endocrinology clinic of the two hospitals. This gives a total of 100 patients per month in each hospital, and for the 6-months study period gave an estimated population of 600 T2D per hospital. However, a maximum of 2 to 6 months clinic appointment is usually given to T2D in UCH, and a maximum of 3 months appointment in FMC, the appointment schedule was based on the extent of glycaemic control. Based on this information, an estimated T2D population for 4-months and 3-months was used to calculate the target sample size for UCH and FMC, respectively. Thus, considering the regular attendee of 100 patients per month in each of the hospital, a total of 700 T2D was used as estimated population to guide sample size determination using the Raosoft® sample size calculator at 95% confidence level and 5% margin of error (http://www.raosoft.com/samplesize.html). This gave a target sample size of 249 T2D participants to be enrolled for the study. Similarly, Average of 20 hypertensive patients regularly attend the weekly medical out-patient cardiology clinic of the two hospitals. This gives a total of 80 patients per month in each hospital, and for the 6-months study period gave an estimated population of 320 hypertensive patients per hospital. However, a maximum of 2 to 6 months clinic appointment is usually given to hypertensive patients in UCH, and a maximum of 3 months appointment in FMC, depending on the extent of control of the blood pressure. Based on this information, an estimated hypertensive patients population for 4-months and 3-months was used to calculate the target sample size for UCH and FMC, respectively. Thus, considering the regular attendee of 80 patients per month in each of the hospital, a total of 560 was used as estimated population to guide sample size determination using the Raosoft® sample size calculator at 95% confidence level and 5% margin of error. This gave a target sample size of 229 hypertensive participants to be enrolled.

Instrument descriptions The baseline questionnaire comprised sections A to F. Section A captured demographic data, section B contained modified International Physical Activity Questionnaire short-form (IPAQ-SF) (IPAQ-SF, 2002) and individual physical activity was calculated as metabolic equivalent task (MET) per week (http://www.ipaq.ki.se). IPAQ -SF instrument measures duration, frequency, intensity of physical activity in leisure-time, work, and doing household tasks in the past seven days. This short version consists of seven items including time spent in walking, vigorous activity, moderate activity, and sedentary activity weekly. Metabolic Equivalent Tasks (MET) values reported by patients were computed. To interpret the modified IPAQ-SF, according to WHO, an adult is expected to have minimum of 600 Metabolic Equivalents (MET) physical activities weekly. Participants were classified as non-adherent and adherent to exercise if he/she has less than 600 and above 600METs per week respectively.

Section C consisted of modified Perceived Dietary Adherence Questionnaire (PDAQ) developed by Assad et al., (2015), to measure patients' perception of dietary adherence. For these items, higher scores reflected higher level of adherence (Assad et al., 2015). However, items four and nine, indicated unhealthy choices (foods high in sugar or fat). For these items, higher scores reflected lower adherence. In computing the total PDAQ score, the scores for these two items were inverted. Although based on a weekly timeframe, it was anticipated that the PDAQ would reflect usual dietary patterns based on knowledge that most people consume similar foods from week to week (Assad et al., 2015). In this study, PDAQ was interpreted by classifying participants as adherent to dietary recommendations if they scored 51 (80%) and above, out of the 63 maximum obtainable score, while those who scored less than 51 (80%) were classified as non-adherent to dietary recommendations. Section D of the instrument contained the 4-items Medication Adherence Questions (MAQ) while section E explored reason(s) for non-adherence to medications, physical activity and dietary recommendations. Section F of the instrument contained the components of educational intervention to resolve non-adherence problems that were identified from the responses to questions in MAQ, IPAQ-SF and PDAQ among patients in the intervention groups. Where necessary, at least one to two clinic appointment was rescheduled to follow-up of the participants in the intervention group. The 6-months post-baseline evaluation employed the same questions in sections B, C, D and E to re-assessed participants in both control and intervention groups, to ascertain the possible change in adherence status to recommended medications, physical activity and dietary management.

Validation and Pre-test of Data Collection Instrument

The questionnaire was assessed for content validity by an endocrinologist and cardiologist in UCH and three pharmacists in the academia in University of Ibadan who were knowledgeable about diabetes mellitus and hypertension. A pre-test was caaried out among twenty-five T2D and hypertensive patients in UCH who were subsequently excluded from the main study. The pre-test was aimed at ascertaining the appropriateness of the data collection procedure as well as the study design. Feedback from the pre-test was used to modified. Some questions on physical activity which were rephrased as open-ended questions. In addition, some food items in the PDAQ that are not native food of the studied population were replaced with their indigenous food with similar calorie in accordance with official recommendations (Atkinson et al., 2008; Evert et al., 2014) for better understanding of the partiicpants. Internal consistency of the question-items in PDAQ and MAQ were determined using Cronbach alpha test with values of 0.87 and 0.76, respectively.

Participants enrollment procedure

Only eligible patients were approached while waiting to consult the attending physicians on endocrinology clinic day of each hospital. At baseline, a total of 249 T2D and 262 hypertensive patients were approached, while 227 (91.2%) T2D and 248 (94.6%) hypertensive patients consented to partake in the study from both hospitals within the study period. Every participant had individualized baseline, and once the 6-months duration of enrolment into the study is completed, then individual participation is terminated. At baseline, participants were administered the questionnaire, while glycaemic status (HbA1c) and blood pressure (BP) were also assessed. However, at the end of the study period, a total of 201 (88.5%) T2D and 200 hypertensive patients completed the study and were those considered for data analysis, 26 (11.5%) T2D and 48 (19.3%) hypertensive patients were lost to follow-up. Of the 201 and 200 who competed the study, a total of 95 T2D patients had HbA1c <7%, 120 hypertensive patients had blood pressure <140/90mmHg and were classified as control group, while 106 T2D patients had HbA1c ≥7% and 80 hypertensive patients had blood pressure ≥140/90mmHg and were classified as uncontrolled/intervention group using the ADA target for diabetes control (ADA, 2018) and according to JNC-7 (Chobanian et al., 2003) respectively. Finger pin-prick blood assay of glycosylated haemoglobin (HbA1c) was done using the clover A1C automated analyser ® (PTS Diagnostics, IN, USA) point-of-care kit, while BP measurements using Omron® digital monitor were taken on two separate occasions at few minutes interval and the average was recorded. Patients' BP and HbA1c were also rechecked after 6-months of interaction to assess the extent of change in the diabetes-specific clinical parameters and hypertension-clinical parameters.

Data collection procedure participants were approached on their clinic days while waiting to meet the physician at each clinic. the structured questionnaire was used to collected baseline information from the participants. Reasons for non-adherence to medication (s) were obtained if any of the questions in the MAQ was answered in affirmative. IPAQ -SF instrument measures duration, frequency, intensity of physical activity in leisure-time, work, and doing household tasks in the past seven days. Participants were classified as non-adherent and adherent to recommended physical activity if he/she has less than 600 and above 600METs per week respectively. Reasons for non-adherence/inability to achieve recommended MET per week were obtained from such participant. Before recommending an increase in physical activity to patients in the intervention group, the participant's current health status was put into consideration based on the information provided by participant on the disease and other comorbid condition(s) been managed for, such as arthritis, heart disease.

Similarly, participants were further evaluated for adherence to dietary recommendation for their disease state using the modified Perceived Dietary Adherence Questionnaire (PDAQ) (Appendix II). The cut off of 51 points of the total of 63 points indicated that the patient have 80% adherence to dietary recommendation. Similarly, participants reason(s) for non-adherence to recommended dietary management was also obtained.

HbA1c/B.P measurement was carried out to assess their clinical outcome at baseline and 6month post-baseline to evaluate their clinical outcome.

Post-baseline individualized education (Intervention) Phase The individualized educational intervention was check using Template for Intervention Description Replication (TIDiER) check list

The individualized intervention was aimed at improving treatment adherence among patients in the intervention group.

The individualized educational intervention was aimed at resolving non-adherence to therapy (medication, diet and physical activity) deficit identified during the face-to-face interview at the baseline. The hospital information leaflets provided for each patient at the hospital clinics during registration which focused on recommended diet and physical activities was employed to further explained the recommended therapy for the patients. Pharmacist who was knowledgeable on the disease state by the virtue of training and several seminars and workshops on diabetes and hypertension management carried out the face-to-face individualize educational intervention. This was done at the clinics while the participants were waiting for their turn to meet with the physician. At least participants were seen twice to ensure their understanding of information provided for them and resolve any for of misunderstanding that might have taken place. During the pretest, the project supervisor assessed the intervention to ensure it was carried out as planned.

Post-intervention phase This phase of the study re-assessed the treatment adherence of all the participants (both control and intervention group). Sections B, C, D, E and F of Appendix II were re-assessed for both control and the intervention group, six months after the educational intervention of the intervention group. This was done to assess if there is any change in the measured parameters from what was obtained at baseline.

Cost estimation The direct medical costs associated with the treatment of diabetes and/or hypertension for six months prior baseline and six months post-baseline were estimated. The direct medical cost items included; cost of all outpatient clinic visit (consultation fee), cost of medications, and cost of laboratory investigations associated with the disease state. Cost of medication(s) was calculated using the daily dose for medications prescribed with reference to the hospital pharmacy department tariff for the study year. Consultation fee is the amount charged by the hospital for a consulting encounter with a physician. Other direct non-medical costs included are; transportation cost to the hospital for patients based on patient's residence and this was estimated using the NURTW tariff for the year of study. Conversion of Nigeria Naira to US Dollar: ₦303 to 1 USD for the year 2017 was based on conversion rate on currency converter (oando.com).

Data Analysis All data was sorted, coded and entered into SPSS version 23.0 for analysis. Descriptive and inferential statistics were employed for analysis. Descriptive a statistics including frequencies, percentages, and means ± standard deviation were used to summarized data.

significance of change in continuous variables, especially the clinical parameters (such as HbA1c, systolic and diastolic blood pressure), physical activity performed weekly, adherence to recommended diet at baseline and six month post-baseline were compared using paired sample t-test and significance was set at P <0.05. Cost of each cost items 6months prior baseline and at 6months post-baseline for each disease state within and between the two facilities were also compared using paired sample t-test. Total cost of management (including all direct cost associated with the disease state) for each group in each disease state before and after the intervention was evaluated with paired sample t-test.

McNemar test was used to evaluate for significant change in responses to MAQ items at baseline and 6-months post-baseline. Chi-square (χ2) was used to test for association between categorical variables (gender, age, educational qualifications and adherence status) at p<0.05.

Being tested
Health education
Keywords
pharmacoeconomics, diabetes, hypertension, direct cost
Medical subject headings
Diabetes Mellitus, Type 2, Diabetes Mellitus, Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Health educationBehavioural

    Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.

Study groups in NCT04712916
Study groupRoleWhat they receive
Intervention groupExperimentalIndividualized education on medication use, appropriate diet and physical activity was given to the participants in intervention group.
Receives: Behavioral: Health education
Control groupNo interventionParticipant received usual care in the clinic. No individualized education on medication use, appropriate diet and physical activity was given to the participants.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in the value of Glycosylated haemoglobin (HbA1c)

    Finger pin-prick blood assay of glycosylated haemoglobin (HbA1c) was done using the clover A1C automated analyser ® (PTS Diagnostics, IN, USA) point-of-care kit

    Measured: Baseline and 6-month post baseline

  2. Change in value of blood pressure readings

    Blood Pressure measurements using Omron® digital monitor were taken on two separate occasions at five minutes interval and the average was recorded for each participant

    Measured: Baseline and 6-month post baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jan 2021
  2. Study start10 Jun 2017
  3. Primary completion20 Sep 2018
  4. Study completion20 Sep 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
401 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04712916
Sponsor's protocol ID
UI/EC/14/0294
Status last verified
Jan 2021
First submitted
13 Jan 2021
Last updated
22 Jan 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Ipingbemi AE, Erhun WO, Adisa R. Pharmacist-led intervention in treatment non-adherence and associated direct costs of management among ambulatory patients with type 2 diabetes in southwestern Nigeria. BMC Health Serv Res. 2021 Sep 22;21(1):1000. doi: 10.1186/s12913-021-06979-z.

    PubMed 34551779

Questions about this trial

What is this clinical trial studying?

A study testing Health education in people with Diabetes Mellitus, Type 2, run by University of Ibadan at 1 site in Nigeria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Nigeria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in the value of Glycosylated haemoglobin (HbA1c) (time frame: Baseline and 6-month post baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04712916, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in